Oncology News

In a recent study, patients with hepatocellular carcinoma who underwent resection were not found to be ideal candidates, according to current guidelines.

Updated results from the HEAT study indicated an overall survival rate of over 50% among patients with primary liver cancer when treated with ThermoDox combined with radiofrequency ablation, according to a press release from Celsion Corporation.

Surveillance for hepatocellular carcinoma was poor among patients with insurance and hepatitis B virus infection without cirrhosis vs. patients with cirrhosis, according to published data in the Journal of Viral Hepatitis.

The FDA granted orphan drug designation to melphalan for the treatment of patients with cholangiocarcinoma, according to a press release from Delcath Systems.

Adults who have higher incomes or have private health insurance are more likely to receive preventive services, which are available for nine out of 10 leading causes of death in the U.S., according to recently published data.

Women with intrahepatic cholestasis of pregnancy had an increased risk for developing hepatobiliary cancer and immune-mediated and cardiovascular diseases over time compared with women who did not, according to study data.

The Singapore Liver Cancer Recurrence Score was accurate in predicting outcomes for Singaporean patients who underwent resection for hepatocellular carcinoma, according to published findings.

Various body composition components, including sarcopenia, intramuscular fat deposition and visceral adiposity, were accurate in predicting mortality and other outcomes in patients with hepatocellular carcinoma, according to study findings.

Blueprint Medicines announced that the FDA has approved two Investigational New Drug applications to begin phase 1 clinical trials for BLU-554 for the treatment of advanced hepatocellular carcinoma and cholangiocarcinoma, and BLU-285 for gastrointestinal stromal tumor, according to a press release from the manufacturer.

Researchers have, for the first time ever, developed a protein that enables noninvasive detection of early-stage liver metastases — as small as approximately 0.24 in diameter — in patients at high-risk for primary and metastatic liver cancers, according to study findings.